Company news

Disc Medicine, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

February 7, 2023

Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis

January 19, 2023

Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

December 26, 2022

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

October 30, 2022

Gemini Therapeutics and Disc Medicine Announce Merger Agreement

August 9, 2022

Gemini Therapeutics Reports 2021 Financial Results

March 9, 2022

Gemini Therapeutics Provides Corporate Update

February 27, 2022

Gemini Therapeutics Provides GEM103 Program Update

January 9, 2022

Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

November 14, 2021

Gemini Therapeutics Announces Poster Presentation at AAO 2021

November 11, 2021

Gemini Therapeutics to Participate in Upcoming Investor Conferences

November 10, 2021

Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit

October 18, 2021

Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 13, 2021

Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy

October 4, 2021

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

September 9, 2021

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

September 8, 2021

Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

August 29, 2021

Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

August 11, 2021

Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

June 21, 2021

Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

May 25, 2021

Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 12, 2021

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

May 12, 2021

Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

May 2, 2021

Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 30, 2021

Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

April 12, 2021

Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

April 11, 2021

Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

March 28, 2021

Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

February 18, 2021

Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants

February 9, 2021

Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer

February 8, 2021

← Newer news releases

Decks

The 5 newest of 16 decks. Every deck is listed under its year.